低级别浆液性卵巢癌全外显子组测序识别与临床结局相关的基因组事件
本研究对63例低级别浆液性卵巢癌(LGSOC)肿瘤组织进行全外显子组测序并结合详细临床注释,依据单核苷酸变异分为cMAPKm(52%)、MAPK-assoc(27%)和MAPKwt(21%)三个亚组。低肿瘤突变负荷(TMB)和染色体1p缺失伴1q获得(CN Chr1pq)分别与较差疾病特异性生存相关(HR 6.43;p<0.001和HR 3.29,p=0.011)。基于基因组的分层分出四组,5年疾病特异性生存率分别为46%、55%、79%和100%。
要点
- LGSOC可分为cMAPKm(52%)、MAPK-assoc(27%)和MAPKwt(21%)三个基因组亚组。
- 低TMB与较差疾病特异性生存相关(HR 6.43;p<0.001)。
- CN Chr1pq与较差疾病特异性生存相关(HR 3.29,p=0.011)。
核心结论
- LGSOC包含多个具有不同临床和分子特征的基因组亚组。
- 染色体1p/1q拷贝数臂破坏和TMB是识别预后较差个体的有前景的方法。
- 需要进一步研究这些观察结果的分子基础。
- MAPKwt病例约占患者的五分之一,NOTCH抑制剂是值得在这些病例中探索的候选治疗策略。
研究设计与样本
- 对具有详细临床注释的LGSOC队列的肿瘤组织全外显子组测序基因组数据进行分析,共分析63例。
主要发现
- 基于单核苷酸变异识别三个亚组:cMAPKm(52%,KRAS/BRAF/NRAS)、MAPK-assoc(27%)和MAPKwt(21%)。
- NOTCH通路破坏发生在所有亚组中。
- TMB、突变特征和复发性拷贝数改变在整个队列中各不相同,染色体1p缺失和1q获得共现(CN Chr1pq)是复发性特征。
- 低TMB和CN Chr1pq分别与较差疾病特异性生存相关(HR 6.43;p<0.001和HR 3.29,p=0.011)。
- 按结局相关的逐步基因组分类分出四组(TMB低;CN Chr1pq;MAPKwt/MAPKassoc;cMAPKm),5年疾病特异性生存率分别为46%、55%、79%和100%。
关键数值与推荐
- cMAPKm亚组占52%,MAPK-assoc亚组占27%,MAPKwt亚组占21%。
- 低TMB与较差疾病特异性生存相关:HR 6.43;p<0.001。
- CN Chr1pq与较差疾病特异性生存相关:HR 3.29,p=0.011。
- 四组5年疾病特异性生存率分别为46%(TMB低)、55%(CN Chr1pq)、79%(MAPKwt/MAPKassoc)和100%(cMAPKm)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要进一步研究这些观察结果的分子基础。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Low-grade serous ovarian carcinoma (LGSOC) is a distinct, rare, ovarian cancer type characterised by younger patient age and intrinsic chemoresistance. Understanding the molecular landscape is crucial for optimising targeted therapy. METHODS: Genomic data from whole exome sequencing of tumour tissue was analysed in a LGSOC cohort with detailed clinical annotation. RESULTS: 63 cases were analysed and three subgroups identified based on single nucleotide variants: canonical MAPK mutant (cMAPKm: 52%, KRAS/BRAF/NRAS), MAPK-associated gene mutation (MAPK-assoc: 27%) and MAPK wild-type (MAPKwt: 21%). NOTCH pathway disruption occurred across all subgroups. Tumour mutational burden (TMB), mutational signatures and recurrent copy number (CN) changes varied across the cohort with co-occurrence of chromosome 1p loss and 1q gain (CN Chr1pq) a recurrent feature. Low TMB and CN Chr1pq were associated with inferior disease-specific survival (HR 6.43; p < 0.001 and HR 3.29, p = 0.011 respectively). Stepwise genomic classification in relation to outcome resulted in four groups (TMB low; CN Chr1pq; MAPKwt/MAPKassoc; cMAPKm). 5 year disease-specific survival was 46%, 55%, 79% and 100% respectively for these groups. The two most favourable genomic subgroups were enriched for the SBS10b mutational signature, particularly the cMAPKm subgroup. CONCLUSIONS: LGSOC comprises multiple genomic subgroups with distinct clinical and molecular features. Chr1pq CN arm disruption and TMB represent promising methods to identify individuals with poorer prognosis. Further investigation of the molecular basis for these observations is required. MAPKwt cases represent around a fifth of patients. NOTCH inhibitors represent a candidate therapeutic strategy worthy of exploration across these cases.
引用
- Thomson JP, Hollis RL, van Baal J, et al. Whole exome sequencing of low grade serous ovarian carcinoma identifies genomic events associated with clinical outcome. Gynecol Oncol. 2023. PMID: 37207500. doi:10.1016/j.ygyno.2023.04.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。